Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6818748 | 0.94 | ADORA1 (0.40) | ALDH1A1LMNAADORA1MEN1KMT2A | |
| SCHEMBL6824899 | 0.91 | ADORA1 (0.38) | ALDH1A1LMNAADORA1MEN1KMT2A | |
| SCHEMBL6818702 | 0.88 | ADORA1 (0.46) | ADORA1HTT | |
| SCHEMBL6822276 | 0.87 | ADORA1 (0.46) | ALDH1A1HPGDRAB9ANPC1ADORA1 | |
| SCHEMBL6822155 | 0.87 | LMNA (0.46) | ALDH1A1LMNAHPGDRAB9ANPC1 | |
| SCHEMBL6824695 | 0.85 | ADORA2A (0.47) | ADORA1 | |
| SCHEMBL6821916 | 0.85 | ADORA1 (0.42) | ALDH1A1HPGDRAB9ANPC1ADORA1 | |
| SCHEMBL6822104 | 0.84 | SMN1; SMN2 (0.42) | ALDH1A1LMNAADORA1MEN1KMT2A | |
| SCHEMBL6818603 | 0.84 | SMN1; SMN2 (0.42) | ALDH1A1LMNAADORA1MEN1KMT2A | |
| SCHEMBL6822136 | 0.84 | ADORA1 (0.46) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | ADRB1, ADRA1D, ADRB3 | ALDH1A1 564/4885LMNA 4472/4885HPGD 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.